Study #2023-0934
Open label phase 2 study of Tasquinimod in patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
MD Anderson Study Status
Enrolling
Treatment Agent
Tasquinimod, Ruxolitinib
Description
To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
Study phase:
Phase II
Physician name:
Lucia Masarova
Department:
Leukemia
For general questions about clinical trials:
1-844-829-9300
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.